Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Zydus acquires skin...

    Zydus acquires skin treatment lotion Melgain from Issar Pharma

    Written by savita thakur thakur Published On 2016-08-09T12:24:55+05:30  |  Updated On 9 Aug 2016 12:24 PM IST
    Zydus acquires skin treatment lotion Melgain from Issar Pharma

    New Delhi : Zydus Group firm Cadila Healthcare said it has acquired Melgain lotion used for treatment of skin depigmentation from Issar Pharma to strengthen its dermatological portfolio.


    Melgain will be marketed in India by Liva Healthcare, a specialty division of the group catering to the dermatological segment, Cadila Healthcare said in a filing to BSE.


    "Zydus also has an option to launch this product in other global markets where it is not available," it added.


    The company, however, did not disclose the financial details of the acquisition.


    Zydus Group Deputy MD Sharvil P Patel said: "Dermatology has been a core focus segment. I believe that this acquisition will strengthen our portfolio of derma brands and will leverage our equity in this key segment."


    Melgain is used for the treatment of Vitiligo, a chronic skin condition characterised by portions of the skin losing their pigment, Cadila Healthcare said.


    Though the reason for the onset of the condition is not known, the most widely accepted view is that depigmentation occurs because Vitiligo is an autoimmune disease, it added.


    Melgain lotion leads to re-pigmentation in most of the patients, the company said.


    "With a strong presence in the hyper pigmentation, acne, hair care and anti-fungal segments, the expansion into the re-pigmentation segment gives Zydus an edge in the fast growing dermatology market which is currently growing at 14 per cent and valued at over Rs 6,000 crore," it added.

    Acquisitionanti-fungalCadila HealthcareIssar PharmaLiva HealthcareMelgainSharvil P Patelskin treatment lotionzydus
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok